REEP5

Summary

REEP5 (receptor accessory protein 5, HGNC:30077) is a protein-coding gene on chromosome 5q22.2, encoding Receptor expression-enhancing protein 5 (Q00765). Plays an essential role in heart function and development by regulating the organization and function of the sarcoplasmic reticulum in cardiomyocytes.

Predicted to be involved in endoplasmic reticulum membrane organization and regulation of intracellular transport. Located in endoplasmic reticulum tubular network.

Source: NCBI Gene 7905 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 31 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_005669

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30077
Approved symbol	REEP5
Name	receptor accessory protein 5
Location	5q22.2
Locus type	gene with protein product
Status	Approved
Aliases	DP1, TB2, D5S346, Yip2e, POB16
Ensembl gene	ENSG00000129625
Ensembl biotype	protein_coding
OMIM	125265
Entrez	7905

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000261482, ENST00000379638, ENST00000474542, ENST00000497856, ENST00000504247, ENST00000511865, ENST00000513339, ENST00000868806, ENST00000938092, ENST00000938093

RefSeq mRNA: 1 — MANE Select: NM_005669 NM_005669

CCDS: CCDS4109

Canonical transcript exons

ENST00000379638 — 5 exons

Exon	Start	End
ENSE00000917819	112921163	112921256
ENSE00001349886	112876385	112878835
ENSE00002049327	112922073	112922227
ENSE00003488169	112887015	112887183
ENSE00003626661	112902380	112902518

Expression profiles

Bgee: expression breadth ubiquitous, 301 present calls, max score 99.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 115.1965 / max 1047.8138, expressed in 1825 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
62966	110.4502	1825
62967	3.7227	1651
62965	1.0237	598

Top tissues by expression

302 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	99.74	gold quality
lateral nuclear group of thalamus	UBERON:0002736	99.72	gold quality
endothelial cell	CL:0000115	99.69	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.68	gold quality
pons	UBERON:0000988	99.45	gold quality
dorsal root ganglion	UBERON:0000044	99.25	gold quality
primary visual cortex	UBERON:0002436	99.25	gold quality
occipital lobe	UBERON:0002021	99.24	gold quality
orbitofrontal cortex	UBERON:0004167	99.24	gold quality
superior vestibular nucleus	UBERON:0007227	99.21	gold quality
parietal lobe	UBERON:0001872	99.18	gold quality
superior frontal gyrus	UBERON:0002661	99.17	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.16	gold quality
substantia nigra pars compacta	UBERON:0001965	99.15	gold quality
renal glomerulus	UBERON:0000074	99.14	gold quality
lateral globus pallidus	UBERON:0002476	99.13	gold quality
postcentral gyrus	UBERON:0002581	99.13	gold quality
entorhinal cortex	UBERON:0002728	99.05	gold quality
metanephric glomerulus	UBERON:0004736	99.04	gold quality
trigeminal ganglion	UBERON:0001675	99.02	gold quality
renal medulla	UBERON:0000362	98.98	gold quality
dorsal plus ventral thalamus	UBERON:0001897	98.95	gold quality
substantia nigra pars reticulata	UBERON:0001966	98.93	gold quality
medulla oblongata	UBERON:0001896	98.90	gold quality
pigmented layer of retina	UBERON:0001782	98.89	gold quality
retina	UBERON:0000966	98.86	gold quality
ventral tegmental area	UBERON:0002691	98.83	gold quality
Brodmann (1909) area 9	UBERON:0013540	98.80	gold quality
kidney epithelium	UBERON:0004819	98.79	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	98.76	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-4	yes	41.73
E-CURD-46	yes	13.35
E-CURD-88	no	3.76
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

119 targeting REEP5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502

Literature-anchored findings (GeneRIF, showing 4)

• To determine the pathogenesis and treatment response of major depressive disorder. REEP5 gene polymorphisms may influence antidepressant treatment response in MDD. (PMID:22795047)
• Depletion of receptor accessory proteins REEP5 and REEP6 causes a decrease in CXC Chemokine Receptor 1 (CXCR1) signaling. (PMID:27966653)
• The sarco-endoplasmic reticulum (SR/ER) plays an important role in the development and progression of many heart diseases. Receptor accessory protein 5 (REEP5), a cardiac enriched, sarco-endoplasmic reticulum (SR/ER) membrane protein,is centrally involved in regulating SR/ER organization and cellular stress responses in cardiac myocytes. (PMID:32075961)
• The REEP5/TRAM1 complex binds SARS-CoV-2 NSP3 and promotes virus replication. (PMID:37768083)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	reep5	ENSDARG00000100742
mus_musculus	Reep5	ENSMUSG00000005873
rattus_norvegicus	Reep5	ENSRNOG00000020167
drosophila_melanogaster	ReepB	FBGN0033906
drosophila_melanogaster	CG4960	FBGN0039371
caenorhabditis_elegans		WBGENE00011401
caenorhabditis_elegans		WBGENE00012180
caenorhabditis_elegans		WBGENE00018930
caenorhabditis_elegans	yop-1	WBGENE00022127

Paralogs (5): REEP1 (ENSG00000068615), REEP6 (ENSG00000115255), REEP2 (ENSG00000132563), REEP3 (ENSG00000165476), REEP4 (ENSG00000168476)

Protein

Protein identifiers

Receptor expression-enhancing protein 5 — Q00765 (reviewed: Q00765)

Alternative names: Polyposis locus protein 1, Protein TB2

All UniProt accessions (5): Q00765, B7Z332, B7Z510, E2QRG8, H0Y8J8

UniProt curated annotations — full annotation on UniProt →

Function. Plays an essential role in heart function and development by regulating the organization and function of the sarcoplasmic reticulum in cardiomyocytes.

Subunit / interactions. Monomer. Homodimer; maybe disulfide-linked. Homotrimer. Interacts with ATL1. Interacts with ATL2. Interacts with ATL3. Interacts with CKAP4. Interacts with RTN4 (isoforms A and B). Interacts with ZFYVE27.

Subcellular location. Endoplasmic reticulum membrane. Sarcoplasmic reticulum membrane.

Tissue specificity. Expressed in heart (at protein level). Expressed in circumvallate papillae and testis.

Domain organisation. The short lumenal loops between transmembrane domains 1 and 2 and between transmembrane domains 3 and 4 may impart a wedge-like configuration, thus deforming membranes.

Similarity. Belongs to the DP1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q00765-1	1	yes
Q00765-2	2

RefSeq proteins (1): NP_005660* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004345	TB2_DP1_HVA22	Family

Pfam: PF03134

UniProt features (14 total): topological domain 5, transmembrane region 4, sequence conflict 2, chain 1, region of interest 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q00765-F1	78.88	0.13

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 242 (showing top): FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP, YANG_BREAST_CANCER_ESR1_BULK_UP, GOLDRATH_ANTIGEN_RESPONSE, BROWNE_HCMV_INFECTION_48HR_DN, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, TIEN_INTESTINE_PROBIOTICS_24HR_UP, GOBP_MEMBRANE_ORGANIZATION, GOBP_ENDOPLASMIC_RETICULUM_ORGANIZATION, RUAN_RESPONSE_TO_TNF_DN, JACKSON_DNMT1_TARGETS_UP

GO Biological Process (3): endoplasmic reticulum organization (GO:0007029), endoplasmic reticulum membrane organization (GO:0090158), regulation of intracellular transport (GO:0032386)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): endoplasmic reticulum (GO:0005783), sarcoplasmic reticulum membrane (GO:0033017), endoplasmic reticulum tubular network (GO:0071782), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020), sarcoplasmic reticulum (GO:0016529)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
endoplasmic reticulum subcompartment	2
organelle organization	1
endomembrane system organization	1
endoplasmic reticulum organization	1
membrane organization	1
intracellular transport	1
regulation of transport	1
regulation of cellular localization	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
endoplasmic reticulum membrane	1
sarcoplasmic reticulum	1
bounding membrane of organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
cellular anatomical structure	1
endoplasmic reticulum	1
sarcoplasm	1

Protein interactions and networks

STRING

1100 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
REEP5	PFAS	O15067	918
REEP5	RTN4	Q9NQC3	901
REEP5	RTN1	Q16799	885
REEP5	RTN2	O75298	824
REEP5	ATL2	Q8NHH9	819
REEP5	ATL3	Q6DD88	819
REEP5	ATL1	Q8WXF7	817
REEP5	ZNF740	Q8NDX6	774
REEP5	RTN3	O95197	749
REEP5	MLH1	P40692	728
REEP5	SRP19	P09132	719
REEP5	MSH2	P43246	717
REEP5	MSH6	P52701	713
REEP5	APC	P25054	712
REEP5	PMS2	P54278	696

IntAct

147 interactions, top by confidence:

A	B	Type	Score
RABAC1	REEP5	psi-mi:“MI:0915”(physical association)	0.740
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
	PMPCB	psi-mi:“MI:0914”(association)	0.640
FPR2	ARL6IP5	psi-mi:“MI:0914”(association)	0.640
OSBPL8	CSNK2A2	psi-mi:“MI:0914”(association)	0.640
LETMD1	REEP5	psi-mi:“MI:0915”(physical association)	0.580
REEP5	PBX3	psi-mi:“MI:0915”(physical association)	0.560
REEP5	SNX1	psi-mi:“MI:0915”(physical association)	0.560
REEP5	ABHD4	psi-mi:“MI:0915”(physical association)	0.560
REEP5	PITPNC1	psi-mi:“MI:0915”(physical association)	0.560
ARFIP2	REEP5	psi-mi:“MI:0915”(physical association)	0.560
ZFYVE27	REEP5	psi-mi:“MI:0914”(association)	0.540
ZFYVE27	REEP5	psi-mi:“MI:0403”(colocalization)	0.540
ZFYVE27	REEP5	psi-mi:“MI:0915”(physical association)	0.540
C3AR1	TMEM120B	psi-mi:“MI:0914”(association)	0.530
TSPAN11	IGLL5	psi-mi:“MI:0914”(association)	0.530
REEP5	SCAMP1	psi-mi:“MI:0914”(association)	0.530
CLEC5A	TSPAN6	psi-mi:“MI:0914”(association)	0.530
GPC3	CLGN	psi-mi:“MI:0914”(association)	0.530
EMC6	EMC8	psi-mi:“MI:0914”(association)	0.530

BioGRID (517): REEP5 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), REEP5 (Proximity Label-MS), ACSL3 (Affinity Capture-MS), GALNT2 (Affinity Capture-MS)

ESM2 similar proteins: A0A8I3PI99, A0M8U1, A7Y521, B5DEN9, C5HGF3, O88544, O94973, P13666, P17427, P18484, P38024, Q00765, Q0VCK5, Q0X0A5, Q13098, Q1RLU8, Q28635, Q2PG42, Q3KNM2, Q3SZA0, Q3T0N3, Q3T126, Q3T178, Q3ZC24, Q4R5E6, Q5F418, Q5I0H4, Q5M7T4, Q5R648, Q5R9B0, Q5R9M4, Q5RE33, Q5ZJ41, Q5ZJD7, Q6DGW9, Q6GM44, Q6NRT5, Q7TQ48, Q8C407, Q8R1Z9

Diamond homologs: A0A509ADH4, B2RZ37, P0CN16, P0CN17, Q00765, Q07764, Q10010, Q12402, Q29RM3, Q2KI30, Q32LG5, Q3ZCI8, Q4KMI4, Q4P0H0, Q4QQW1, Q4WTW3, Q51VY4, Q5BB01, Q5BL63, Q5HZP8, Q5R598, Q5RE33, Q5XI60, Q60870, Q66IF1, Q682H0, Q6AZM3, Q6BWH8, Q6CE07, Q6CP93, Q6FMU3, Q6NLY8, Q6NUK4, Q6PBX9, Q75A56, Q7ZVX5, Q871R7, Q8BGH4, Q8K072, Q8LE10

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
REEP5	“up-regulates activity”	CXCR1	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 161 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
intra-Golgi vesicle-mediated transport	5	18.4×	3e-03
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	6	14.1×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

31 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	21
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1803764	NC_000005.10:g.112837231_112890913del	Pathogenic

SpliceAI

1421 predictions. Top by Δscore:

Variant	Effect	Δscore
5:112887010:CTTA:C	donor_loss	1.0000
5:112887011:TTACC:T	donor_loss	1.0000
5:112887012:TACCT:T	donor_loss	1.0000
5:112887014:CCTT:C	donor_gain	1.0000
5:112887179:CCACA:C	acceptor_gain	1.0000
5:112887180:CACA:C	acceptor_gain	1.0000
5:112887180:CACAC:C	acceptor_gain	1.0000
5:112887182:CA:C	acceptor_gain	1.0000
5:112887184:C:CC	acceptor_gain	1.0000
5:112902375:CATA:C	donor_loss	1.0000
5:112902376:ATACC:A	donor_loss	1.0000
5:112902377:TACCT:T	donor_loss	1.0000
5:112902378:ACC:A	donor_loss	1.0000
5:112902379:C:CG	donor_loss	1.0000
5:112902514:TAATT:T	acceptor_gain	1.0000
5:112902516:ATTC:A	acceptor_loss	1.0000
5:112902517:TT:T	acceptor_gain	1.0000
5:112902518:TC:T	acceptor_loss	1.0000
5:112902519:C:CC	acceptor_gain	1.0000
5:112902519:C:T	acceptor_loss	1.0000
5:112902520:T:A	acceptor_loss	1.0000
5:112902528:A:T	acceptor_gain	1.0000
5:112902529:G:C	acceptor_gain	1.0000
5:112902529:G:GC	acceptor_gain	1.0000
5:112921157:ACTT:A	donor_loss	1.0000
5:112921158:CTT:C	donor_loss	1.0000
5:112921159:TTA:T	donor_loss	1.0000
5:112921160:TAC:T	donor_loss	1.0000
5:112921161:A:AC	donor_gain	1.0000
5:112921161:ACGAG:A	donor_loss	1.0000

AlphaMissense

1249 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:112902380:C:A	K117N	0.999
5:112902380:C:G	K117N	0.999
5:112902471:A:G	L87P	0.999
5:112921172:G:T	A68D	0.999
5:112902450:C:T	G94D	0.998
5:112902463:A:G	W90R	0.998
5:112902463:A:T	W90R	0.998
5:112902511:C:G	A74P	0.998
5:112902451:C:G	G94R	0.997
5:112902475:A:G	W86R	0.997
5:112902475:A:T	W86R	0.997
5:112921179:A:C	Y66D	0.997
5:112921187:C:T	G63E	0.997
5:112887163:G:C	C124W	0.996
5:112887165:A:G	C124R	0.996
5:112887168:A:G	W123R	0.996
5:112887168:A:T	W123R	0.996
5:112887173:A:G	L121P	0.996
5:112902461:C:A	W90C	0.996
5:112902461:C:G	W90C	0.996
5:112902471:A:T	L87Q	0.996
5:112921164:A:G	S71P	0.996
5:112921170:A:C	Y69D	0.996
5:112887140:C:T	G132E	0.995
5:112887183:A:G	C118R	0.995
5:112902466:A:G	Y89H	0.995
5:112921173:C:G	A68P	0.995
5:112921188:C:G	G63R	0.995
5:112921188:C:T	G63R	0.995
5:112921190:A:T	I62K	0.995

dbSNP variants (sampled 300 via entrez): RS1000001302 (5:112907516 G>A), RS1000051314 (5:112895273 G>A), RS1000138368 (5:112910827 C>T), RS1000168520 (5:112917242 C>T), RS1000200103 (5:112917480 C>A,G), RS1000307309 (5:112877842 T>A), RS1000313734 (5:112922294 G>A,C,T), RS1000346703 (5:112888905 G>A,C), RS1000450012 (5:112906698 A>C), RS1000489926 (5:112922420 C>T), RS1000583895 (5:112877543 G>A), RS1000584898 (5:112906445 TACATAC>T), RS1000585214 (5:112881974 G>T), RS1000707290 (5:112894701 A>G), RS1000765578 (5:112911909 A>T)

Disease associations

OMIM: gene MIM:125265 | disease phenotypes: MIM:175100

GenCC curated gene-disease

Mondo (1): familial adenomatous polyposis 1 (MONDO:0021056)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST000246_17	Attention deficit hyperactivity disorder	8.000000e-06
GCST006268_207	Reaction time	4.000000e-08
GCST006268_510	Reaction time	3.000000e-08
GCST011494_23	Daytime nap	2.000000e-11

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008393	reaction time measurement
EFO:0007828	daytime rest measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295797 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

2 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs153549	Efficacy	3	citalopram;fluoxetine;paroxetine;sertraline	Major Depressive Disorder
rs153560	Efficacy	3	citalopram;fluoxetine;paroxetine;sertraline	Major Depressive Disorder

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs153549	REEP5	3	3.00	1	citalopram;fluoxetine;paroxetine;sertraline
rs153560	REEP5	3	3.00	1	citalopram;fluoxetine;paroxetine;sertraline

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression	6
trichostatin A	affects cotreatment, increases expression	3
bisphenol A	affects cotreatment, increases expression	2
Air Pollutants	increases abundance, decreases expression, affects expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Cyclosporine	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
tetrahydropalmatine	decreases expression	1
methylparaben	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
nefazodone	affects cotreatment, decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
bisphenol B	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol AF	increases expression	1
Atazanavir Sulfate	affects cotreatment, decreases expression	1
Acetaminophen	affects cotreatment, decreases expression	1
Cadmium	decreases reaction, increases abundance, increases palmitoylation	1
Chenodeoxycholic Acid	affects cotreatment, decreases expression	1
Cisplatin	decreases expression, decreases reaction	1
Coumestrol	affects cotreatment, decreases expression	1
Deoxycholic Acid	affects cotreatment, decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diazinon	increases methylation	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4232643	Binding	Binding affinity to REEP5 cysteine residue in human 786-O cell soluble proteomic lysate at 5 uM incubated for 1 hr followed by cell lysis by IA-alkyne probe based isoTOP-ABPP analysis	Covalent inhibitors of nicotinamide N-methyltransferase (NNMT) provide evidence for target engagement challenges in situ. — Bioorg Med Chem Lett

Cellosaurus cell lines

12 cell lines: 9 embryonic stem cell, 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1IL	H9 AAVS1-TRE3G-NGN2 CCPG1-/- Keima-REEP5	Embryonic stem cell	Female
CVCL_D1IN	H9 AAVS1-TRE3G-NGN2 RETREG1-/- Keima-REEP5	Embryonic stem cell	Female
CVCL_D1IQ	H9 AAVS1-TRE3G-NGN2 RETREG3-/- Keima-REEP5	Embryonic stem cell	Female
CVCL_D1IS	H9 AAVS1-TRE3G-NGN2 RETREG3-/- RETREG2-/- Keima-REEP5	Embryonic stem cell	Female
CVCL_D1IU	H9 AAVS1-TRE3G-NGN2 RETREG3-/- RETREG2-/- RETREG1-/- Keima-REEP5	Embryonic stem cell	Female
CVCL_D1IW	H9 AAVS1-TRE3G-NGN2 RETREG3-/- RETREG2-/- RETREG1-/- TEX264-/- Keima-REEP5	Embryonic stem cell	Female
CVCL_D1IY	H9 AAVS1-TRE3G-NGN2 RETREG3-/- RETREG2-/- RETREG1-/- TEX264-/- CCPG1-/- Keima-REEP5	Embryonic stem cell	Female
CVCL_D1J0	H9 AAVS1-TRE3G-NGN2 TEX264-/- Keima-REEP5	Embryonic stem cell	Female
CVCL_D1J2	H9 AAVS1-TRE3G-NGN2 RETREG2-/- Keima-REEP5	Embryonic stem cell	Female
CVCL_D1QD	Abcam K-562 REEP5 KO	Cancer cell line	Female

Clinical trials (associated diseases)

12 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00140894	PHASE4	TERMINATED	A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
NCT00585312	PHASE3	TERMINATED	Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
NCT00319007	PHASE2	UNKNOWN	Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis
NCT01187901	PHASE2	COMPLETED	A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
NCT03095703	PHASE2	COMPLETED	Sirolimus and Familial Adenomatous Polyposis (FAP)
NCT02113202	PHASE1	COMPLETED	Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW
NCT03649971	PHASE1	COMPLETED	A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
NCT05014360	PHASE1	COMPLETED	A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
NCT01604564	Not specified	COMPLETED	Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients
NCT03027401	Not specified	WITHDRAWN	Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
NCT04948398	Not specified	NO_LONGER_AVAILABLE	Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
NCT06435533	Not specified	RECRUITING	Cold Atmospheric Plasma for the Endoscopic Treatment of Duodenal Polyps in Patients With Familial Adenomatous Polyposis